Patents by Inventor Andrew S. Judd

Andrew S. Judd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200002432
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 8, 2017
    Publication date: January 2, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20190343961
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: November 14, 2019
    Inventors: Erwin R. Boghaert, Milan Bruncko, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20190153107
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20190153108
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20190142941
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: January 4, 2019
    Publication date: May 16, 2019
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Macrocyclic MCL-1 inhibitors and methods of use
    Publication number: 20190144465
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, R15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: May 16, 2019
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • Macrocyclic MCL-1 inhibitors and methods of use
    Publication number: 20190055264
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: February 21, 2019
    Inventors: Patrick B. Brady, Wilfried Braje, Yujia Dai, George A. Doherty, Jane Gong, Katja Jantos, Cheng Ji, Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Anthony Mastracchio, Roberto M. Risi, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Xilu Wang, Michael D. Wendt, Yiyun Yu, Guidong Zhu, Thomas D. Penning
  • ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20170355769
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 14, 2017
    Inventors: Lorenzo Benatuil, Milan Bruncko, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur
  • Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
    Publication number: 20170182179
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 29, 2017
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Erwin R. Boghaert, Milan Bruncko, George Doherty, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20160339117
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 24, 2016
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
    Publication number: 20160158377
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 9, 2016
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
    Patent number: 9051327
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: June 9, 2015
    Assignee: AbbVie Inc.
    Inventors: Gui-Dong Zhu, Jane Gong, Andrew S. Judd, Virajkumar B. Gandhi, Alexander R. Shoemaker, Thomas D. Penning, Michael R. Michaelides, Chunqiu Lai, Keith W. Woods
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Patent number: 8901152
    Abstract: The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: December 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Andrew S. Judd, Mathew M. Mulhern, Rajesh R. Iyengar, Philip R. Kym, Andrew J. Souers
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 8883784
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Andrew S. Judd, Andrew J. Souers, Zhi-Fu Tao
  • PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES
    Publication number: 20140296220
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 2, 2014
    Inventors: Gui-Dong Zhu, Jane Gong, Andrew S. Judd, Virajkumar B. Ghandi, Alexander R. Shoemaker, Thomas D. Penning, Michael R. Michaelides, Chunqiu Lai, Keith W. Woods
  • Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
    Patent number: 8796289
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: August 5, 2014
    Assignee: AbbVie Inc.
    Inventors: Gui-Dong Zhu, Jane Gong, Andrew S. Judd, Virajkumar B. Ghandi, Alexander R. Shoemaker, Thomas D. Penning, Michael R. Michaelides, Chunqui Lai, Keith W. Woods
  • Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
    Patent number: 8691810
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: April 8, 2014
    Assignee: AbbVie Inc.
    Inventors: Michael R. Michaelides, Andrew S. Judd, Shannon R. Fix-Stenzel, Richard F. Clark, Bryan K. Sorensen, Zhiqin Ji
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20140073640
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: August 12, 2013
    Publication date: March 13, 2014
    Inventors: Andrew S. Judd, Andrew J. Souers, Zhi-Fu Tao
  • PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES
    Publication number: 20130023523
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
    Type: Application
    Filed: July 19, 2012
    Publication date: January 24, 2013
    Applicant: ABBOTT LABORATORIES
    Inventors: Gui-Dong Zhu, Jane Gong, Andrew S. Judd, Virajkumar B. Ghandi, Alexander R. Shoemaker, Thomas D. Penning, Michael R. Michaelides, Chunqiu Lai, Keith W. Woods
  • INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
    Publication number: 20120277223
    Abstract: The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: July 16, 2012
    Publication date: November 1, 2012
    Inventors: Andrew S. Judd, Mathew M. Mulhern, Rajesh R. lyengar, Philip R. Kym, Andrew J. Souers